Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular ses

Here is how Cardiol Therapeutics Inc. (CRDL) and Charles River Laboratories (CRL) have performed com

Does Cardiol Therapeutics Inc. (CRDL) have what it takes to be a top stock pick for momentum investo

Canaccord Genuity analyst Edward Nash maintains Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and

Cardiol Therapeutics NASDAQ: CRDL is advancing its synthetic, pharmaceutical-grade cannabidiol formu

Cardiol Therapeutics (NASDAQ: CRDL - Get Free Report) is expected to post its Q2 2026 results after

TORONTO, Aug. 5, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol

HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with

The publication comes as the pivotal Phase III MAVERIC trial nears full patient enrollment. The publ

• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC

TORONTO, July 9, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol"

TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol

TORONTO, June 23, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol

TORONTO, May 14, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol"

Results demonstrate CardiolRx™ may represent a paradigm shift in the treatment of patients with recu

Leading enrolling centers include Cleveland Clinic, three major campuses of the Mayo Clinic, Northwe

Corcept Therapeutics (NASDAQ: CORT - Get Free Report) and Cardiol Therapeutics (NASDAQ: CRDL - Get F

Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX:

Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a l

Initiated pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis and surpassed 50%

Cardiol Therapeutics (NASDAQ: CRDL) used a presentation at TD Cowen's 46th Annual Healthcare Confere

Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (T

HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with

Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a l

Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (T

Cardiol Therapeutics Inc. (TSE: CRDL - Get Free Report) shares fell 7.1% during mid-day trading on T

Cardiol Therapeutics Inc. (TSE: CRDL - Get Free Report) shares fell 7.1% during trading on Thursday.

Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a l

HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with

Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and im

Cardiol Therapeutics (NASDAQ:CRDL) reported quarterly losses of $(0.09) per share which met the anal

Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardi

MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is ful

MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is ful

Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable

Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a c

HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Cardiol Therapeutics (NASDAQ

HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Cardiol Therapeutics (NASDAQ

HC Wainwright & Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:CRDL) w

Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the fi

HC Wainwright & Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:CRDL) w

HC Wainwright & Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:CRDL) w

HC Wainwright & Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:CRDL) w

HC Wainwright & Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:CRDL) w

Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-

Gainers Near Intelligence, Inc. (NASDAQ: NIR) shares rose 34.1% to $0.2801 in pre-market trading af